Home/Pipeline/Amyloid Biomarker Assays

Amyloid Biomarker Assays

Alzheimer's disease

Commercial/DevelopmentActive

Key Facts

Indication

Alzheimer's disease

Phase

Commercial/Development

Status

Active

Company

ADx NeuroSciences

About ADx NeuroSciences

ADx NeuroSciences, founded in 2008 and based in Ghent, Belgium, is a specialized diagnostics company developing innovative biomarker assays for neurodegenerative disorders like Alzheimer's, Parkinson's, and Motor Neuron Diseases. Its core capabilities include proprietary antibody generation and the development of robust, fit-for-purpose immunoassays tailored for drug development and clinical research. Operating as a Fujirebio company, ADx serves pharmaceutical clients and technology providers, aiming to improve clinical trial success and patient outcomes through precise biomarker measurement.

View full company profile

Therapeutic Areas

Alzheimer's disease Parkinson's disease Motor Neuron Diseases Psychiatric disorders Sleep disorders

Other Alzheimer's disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active